Company profile
Cardiol Therapeutics Inc.
NASDAQ:CRDLBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Cannabidiol | approved | — | 28 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04615949 | phase2_3 | terminated | 2021-04-30 | 2022-11-30 | Cardiol Therapeutics Inc. | Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors |
| NCT06708299 | phase3 | recruiting | 2025-04-07 | 2026-09-21 | Cardiol Therapeutics Inc. | CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) |
| NCT05180240 | phase2 | completed | 2022-07-28 | 2025-01-31 | Cardiol Therapeutics Inc. | Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis |
| NCT05494788 | phase2 | completed | 2023-01-09 | 2024-06-15 | Cardiol Therapeutics Inc. | Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot) |
FDA applications (0)
No records yet.